Mortality reduction with PCSK9 inhibition: A  case of cautious optimism

The advent of monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) has been a great achievement in clinical lipidology and cardiovascular medicine. Both alirocumab and evolocumab have been shown to significantly reduce cardiovascular events and are generally well tolerated, even in patients who achieve very low levels of low-density lipoprotein cholesterol (LDL-C).1,2 A question that remains unclear, however, is whether these therapies reduce mortality in high-risk patients on background statin therapy.

Source: Journal of Clinical Lipidology - July 3, 2019 Category: Lipidology Authors: Dave L. Dixon, Salim S. Virani Tags: Editorial Source Type: research